Clindamycin 300mg Capsules
₦24,000.00
Clindamycin 300 mg capsules are an antibiotic medication used to treat various bacterial infections. It is particularly effective against anaerobic bacteria and certain protozoal infections.
Key Features:
- Active Ingredient:
- Clindamycin: A lincosamide antibiotic that works by inhibiting bacterial protein synthesis, effectively stopping the growth of susceptible bacteria.
- Indications:
- Commonly prescribed for:
- Skin and soft tissue infections
- Respiratory tract infections (e.g., pneumonia)
- Bone and joint infections (e.g., osteomyelitis)
- Certain dental infections
- Infections caused by anaerobic bacteria
- Commonly prescribed for:
- Dosage Form:
- Available as capsules for oral administration.
Usage:
- Dosage:
- The dosage should be determined by a healthcare provider, often ranging from 150 mg to 300 mg taken every 6 to 8 hours, depending on the type and severity of the infection.
- Administration:
- Take the capsules with a full glass of water. It can be taken with or without food, but taking it with food may help reduce gastrointestinal discomfort.
Precautions:
- Allergies:
- Inform your healthcare provider of any known allergies to clindamycin or lincomycin.
- Side Effects:
- Possible side effects may include gastrointestinal disturbances (nausea, diarrhea, abdominal pain), skin rash, and, rarely, Clostridium difficile-associated diarrhea. Report any severe or persistent side effects to your healthcare provider.
- Interactions:
- Discuss any other medications you are taking with your healthcare provider to avoid potential interactions, especially with other antibiotics or medications affecting gut flora.
Storage:
- Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
- Very secured payment methods
- Shipping will be calculated on checkout
- Please note that price may increase due to exchange rate, ensure updated price before making payment
Dispensing supervised byPharm. Tope Kareem, B.PharmPCN Reg. 023669
Last updated 28 August 2026How we write and check this informationPCN Premises Licence LAG20247B39C9





Reviews
There are no reviews yet.